骨粗鬆症：世界市場（医薬品市場予測及び分析～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 14
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 19
2.3 Upcoming Related Reports 19
3 Disease Overview 20
3.1 Etiology and Pathophysiology 20
3.1.1 Etiology 20
3.1.2 Pathophysiology 23
3.1.3 Risk Factors 24
3.1.4 Quality of Life 24
3.2 Symptoms 25
4 Epidemiology 26
4.1 Risk Factors and Comorbidities 26
4.1.1 Advanced age and female sex are the leading risk factors for osteoporosis 26
4.1.2 Low body mass index (BMI) and physical inactivity can lead to significant bone loss 26
4.1.3 Previous osteoporotic fracture increases risk of subsequent fracture 27
4.1.4 Certain diseases and medications increase the risk of osteoporosis 28
4.1.5 Malnutrition and a nutrient-poor diet decrease BMD 28
4.1.6 Smoking is an independent risk factor for osteoporosis 29
4.1.7 Limited daily alcohol consumption may have a protective effect 29
4.2 Global and Historical Trends 30
4.2.1 United States 30
4.2.2 Five EU Markets 31
4.2.3 Asia 32
4.3 Forecast Methodology 34
4.3.1 Sources Used 35
4.3.2 Forecast Assumptions and Methods 38
4.3.3 Sources Not Used 41
4.4 Epidemiology Forecast (2012-2022) 42
4.4.1 Total Prevalent Cases of Osteoporosis 42
4.4.2 Age-Specific Prevalent Cases of Osteoporosis 43
4.4.3 Sex-Specific Total Prevalent Cases of Osteoporosis 44
4.5 Discussion 46
4.5.1 The Strength of GlobalData’s Epidemiologic Projections 48
5 Disease Management 49
5.1 Treatment Overview 49
5.1.1 Diagnosis and Referral 49
5.1.2 Treatment Guidelines 50
5.1.3 Disease Management 51
5.2 United States 54
5.2.1 Diagnosis 54
5.2.2 Clinical Practice 55
5.3 United Kingdom 56
5.3.1 Diagnosis 56
5.3.2 Clinical Practice 57
5.4 France 58
5.4.1 Diagnosis 58
5.4.2 Clinical Practice 58
5.5 Germany 59
5.5.1 Diagnosis 59
5.5.2 Clinical Practice 60
5.6 Spain 61
5.6.1 Diagnosis 61
5.6.2 Clinical Practice 61
5.7 Italy 62
5.7.1 Diagnosis 62
5.7.2 Clinical Practice 63
5.8 Japan 63
5.8.1 Diagnosis 63
5.8.2 Clinical Practice 63
5.9 China 64
5.9.1 Diagnosis 64
5.9.2 Clinical Practice 65
5.10 India 65
5.10.1 Diagnosis 65
5.10.2 Clinical Practice 66
6 Competitive Assessment 67
6.1 Overview 67
6.2 Strategic Competitor Assessment 67
6.3 Product Profiles – Major Brands 71
6.3.1 Actonel (risedronate sodium) 71
6.3.2 Evista (raloxifene hydrochloride) 75
6.3.3 Reclast (zolendronic acid) 79
6.3.4 Forteo (teriparatide) 83
6.3.5 Prolia (denosumab) 87
6.3.6 Protelos (strontium ranelate) 91
6.3.7 Miacalcin and Fortical (calcitonin-salmon) 94
6.3.8 Viviant/Conbriza (bazedoxifene) 99
6.3.9 Recalbon/Bonoteo (minodronic acid hydrate) 103
6.3.10 Alendronate sodium 106
6.3.11 Ibandronate 109
7 Opportunity and Unmet Need 111
7.1 Overview 111
7.2 Unmet Needs 111
7.2.1 Disease Awareness and Early Diagnosis 111
7.2.2 Patient Compliance 112
7.2.3 Efficacy 113
7.2.4 Safety 113
7.2.5 Treatment Cost 114
7.2.6 Earlier Intervention 114
7.3 Unmet Needs Gap Analysis 115
7.4 Opportunity 1: Dual-Action Therapies 116
7.5 Opportunity 2: Osteoporosis Prevention Therapies 117
7.6 Opportunity 3: Dosing and Administration 118
8 Pipeline Assessment 119
8.1 Overview 119
8.2 Clinical Trial Mapping 120
8.2.1 Clinical Trials by Country 120
8.3 Clinical Trials by Phase and Trial Status 120
8.3.1 Overview of Selected Late-Phase Development Programs 122
8.4 Promising Drugs in Clinical Development 123
8.4.1 Aprela (bazedoxifene and conjugated estrogens) 124
8.4.2 Romosozumab (AMG-785) 131
8.4.3 Odanacatib 137
8.4.4 BA-058 143
8.4.5 PTH(1-31)NH2 148
8.4.6 Ostora (recombinant salmon calcitonin) 153
9 Current and Future Players 158
9.1 Overview 158
9.2 Trends in Corporate Strategy 159
9.3 Company Profiles 160
9.3.1 Amgen 160
9.3.2 Merck 162
9.3.3 Eli Lilly 165
9.3.4 Pfizer 168
9.3.5 Radius Health 170
10 Market Outlook 173
10.1 Global Markets 173
10.1.1 Forecast 173
10.1.2 Drivers and Barriers – Global Issues 175
10.2 United States 177
10.2.1 Forecast 177
10.2.2 Key Events 180
10.2.3 Drivers and Barriers 180
10.3 France 182
10.3.1 Forecast 182
10.3.2 Key Events 185
10.3.3 Drivers and Barriers 185
10.4 Germany 187
10.4.1 Forecast 187
10.4.2 Key Events 190
10.4.3 Drivers and Barriers 190
10.5 Italy 192
10.5.1 Forecast 192
10.5.2 Key Events 195
10.5.3 Drivers and Barriers 195
10.6 Spain 197
10.6.1 Forecast 197
10.6.2 Key Events 200
10.6.3 Drivers and Barriers 201
10.7 United Kingdom 202
10.7.1 Forecast 202
10.7.2 Key Events 205
10.7.3 Drivers and Barriers 205
10.8 Japan 208
10.8.1 Forecast 208
10.8.2 Key Events 211
10.8.3 Drivers and Barriers 211
10.9 India 213
10.9.1 Forecast 213
10.9.2 Key Events 215
10.9.3 Divers and Barriers 216
10.10 China 217
10.10.1 Forecast 217
10.10.2 Key Events 219
10.10.3 Drivers and Barriers 220
11 Appendix 221
11.1 Bibliography 221
11.2 Abbreviations 237
11.3 Methodology 240
11.4 Forecasting Methodology 240
11.4.1 Diagnosed Osteoporosis Patients 240
11.4.2 Percent Drug-Treated Patients 240
11.4.3 Drugs Included in Each Therapeutic Class 241
11.4.4 Launch and Patent Expiry Dates 241
11.4.5 General Pricing Assumptions 242
11.4.6 Individual Drug Assumptions 242
11.4.7 Generic Erosion 246
11.4.8 Pricing of Pipeline Agents 246
11.5 Physicians and Specialists Included in this Study 247
11.5.1 About the Authors 248
11.5.2 Global Head of Healthcare 249
11.6 About GlobalData 250
11.7 Contact Us 250
11.8 Disclaimer 250